NPHC - Nutra Pharma Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0000 (0.00%)
At close: 3:42PM EDT
Stock chart is not supported by your current browser
Previous Close0.0003
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0003 - 0.0003
52 Week Range0.0001 - 0.0023
Avg. Volume6,407,921
Market Cap1.23M
Beta (3Y Monthly)11.44
PE Ratio (TTM)N/A
EPS (TTM)-0.0030
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.53
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Nutra Pharma Responds to FDA Warning Letter

    CORAL SPRINGS, Fla., April 10, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE  -- Nutra Pharma Corporation (NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that the Company has responded to an FDA warning letter that was issued on March 11th regarding the company’s website and social media sites for the sales and marketing of their Nyloxin® products.

  • MarketWatch2 months ago

    FDA says Nutra Pharma illegally markets unapproved products claiming to treat addiction and chronic pain

    The Food and Drug Administration said on Tuesday it had posted a warning letter to Nutra Pharma Corp. for illegally marketing unapproved products for treating pain and addiction. "Health fraud scams like these are inexcusable," said FDA Commissioner Scott Gottlieb. Nutra Pharma makes a line of products that supposedly contain cobra venom, something the company says can be used to treat chronic pain, cancer, arthritis and heroin addiction. "These products have not been demonstrated to be safe or effective and may keep some patients from seeking appropriate, FDA-approved therapies," the FDA said in a statement. The regulatory agency is seeking a response from Nutra Pharma within 15 working days. Nutra Pharma trades over the counter.

  • We're sorry this is all we were able to find about this topic.